A regimen of trastuzumab, paclitaxel, carboplatin and gemcitabine has favourable efficacy in advanced, HER2-positive urothelial cancer

By  

Inpharma, Vol. 1, Iss. 1591, 2007-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

By Coyne C. P.   Ross Matt   Bailey John  

Journal of Drug Targeting, Vol. 17, Iss. 6, 2009-07 ,pp. : 474-489

Informa Healthcare

Access to resources Recommend Favorite

Identifying the challenges of biomarkers that predict response to HER2-directed therapies

By Iyengar Neil M   Morris Patrick G  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 11, 2013-08 ,pp. : 1437-1440

Informa Healthcare

Access to resources Recommend Favorite

Early improvement predicts response

By Bech P.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 189-190

Elsevier

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite